Biocurion is building a portfolio of independent, wholly-owned life science companies — each focused on a large underserved therapeutic need and supported by one integrated holding platform.
A holding company model for modern biotech: independent science companies, shared infrastructure, disciplined capital allocation, and multiple development pathways.
Each vertical operates with its own science, IP, leadership, and capital structure — enabling independent scientific development and asset-level focus.
Shared regulatory expertise, CMC capabilities, clinical strategy, and BD relationships compress timelines and reduce duplicative cost.
Five verticals, five development pathways: licensing, regulatory strategy, government preparedness, and commercial partnerships.
Programs positioned around IND-enabling work, clinical development, and meaningful scientific and regulatory inflection points.
Each wholly-owned subsidiary is purpose-built around a distinct scientific domain, development pathway, and development pathway.
Integrated approaches to cancer diagnosis and treatment through molecular imaging, targeted therapeutics, and data-driven treatment strategies.
Targeted imaging and radiopharmaceutical programs designed to accelerate diagnosis and improve care for children with rare diseases.
Precision neuroscience platform focused on upstream neuroinflammation, synaptic resilience, and biomarker-guided development.
Integrated detection, diagnosis, and targeted therapeutics for sepsis, melioidosis, Ebola, Lassa Fever, and antimicrobial-resistant pathogens.
Radioprotective and radiomitigative therapeutics for acute radiation syndrome, space medicine, oncology care, and military readiness.
Biocurion provides exposure to multiple independent biotech companies, multiple scientific domains, multiple clinical pathways, and multiple development pathways.
We select domains where unmet need, regulatory incentives, and validated collaboration markets converge.
Each subsidiary has its own scientific direction, regulatory strategy, IP ownership, and capital structure.
Biocurion provides strategic oversight, capital allocation, operating support, and structural governance.
Each company is structured for its own path: clinical development, regulatory strategy, licensing, government preparedness, or commercial partnership.
Biocurion news, portfolio milestones, strategic transactions, and market developments shaping the future of precision medicine.
The combination underscores the strategic value of scaled radiopharmaceutical platforms spanning molecular imaging, targeted therapeutics, manufacturing, and commercial infrastructure.
Read Reuters coverageBiocurion combines independently valuable scientific companies with disciplined capital allocation, centralized infrastructure, and portfolio-level strategic flexibility.
Explore the platformBiocurion welcomes discussions with pharmaceutical partners, academic institutions, health systems, government agencies, and strategic capital providers.
Connect with BiocurionWe welcome inquiries from pharmaceutical partners, clinicians, researchers, academic collaborators, institutional investors, media, and prospective team members. Submit the form below and your inquiry will be routed to the appropriate Biocurion team.
Use the form to contact Biocurion about partnerships, licensing, clinical research, investor relations, media, careers, privacy requests, or general inquiries.
Strategic partnerships, licensing, co-development, technology evaluation, and collaboration opportunities.
Clinical investigators, physicians, researchers, academic institutions, and trial collaboration opportunities.
Institutional investors, family offices, strategic capital partners, and other qualified investment inquiries.
Press, speaking engagements, career interest, privacy requests, and general corporate inquiries.
Biocurion
United States
www.biocurion.com
Biocurion and its portfolio companies respect your privacy. This website may collect contact information submitted through forms, technical usage information, and cookie-based analytics data.
Information is used to respond to inquiries, support business development and clinical collaboration, improve website functionality, and comply with applicable legal obligations.
We do not sell personal information. We may share information with service providers who support website hosting, analytics, communications, and compliance.
For privacy requests, use the website inquiry form and select “Privacy Request.”
We use strictly necessary cookies for site functionality and optional analytics cookies to understand site traffic and improve the digital experience.
You may accept cookies, reject optional cookies, or adjust preferences through your browser settings at any time.
This website is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase securities.
Statements regarding development programs, expected milestones, market opportunities, potential transactions, and future performance are forward-looking and subject to risks, uncertainties, regulatory review, and change.
Programs described on this website are investigational and have not been approved by the U.S. Food and Drug Administration or other regulatory authorities unless expressly stated.